We used an "omics" approach — profiling liver biopsies, plasma, and urine samples — to detect a reproducible signature of lipid metabolites, aqueous intracellular metabolites, SNPs, and mRNA transcripts in a double-blinded study of patients with different stages of nonalcoholic fatty liver disease (NAFLD). Using linear discriminant analysis, we identified a panel of 20 plasma metabolites that can be used to differentiate between NASH and steatosis. This identification of differential biomolecular signatures has the potential to improve clinical diagnosis and facilitate therapeutic intervention of NAFLD.
Reference: Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. J Lipid Res. 2015 Mar;56(3):722-36. doi: 10.1194/jlr.P056002. Epub 2015 Jan 17.
We performed both lipidomics studies and microarray analysis of RAW 264.7 cells and primary macrophages, using various treatments. These studies were conducted using standardized protocols for isolation, expansion and analysis of primary macrophages and macrophage cell lines. Central preparation of cells enable LIPID MAPS lipidomics cores to characterize lipids under the most uniform conditions possible and allow results in one core unit to be directly compared to results in other core units.
Measurements of lipid quanitities present in various cell fractions (cytoplasm, ER, mitochondria, nucleus, plasma membrane) for control and treatment with Kdo2-Lipid A
LIPID MAPS uses cookies to keep the site working, to remember your choices, and — only if you allow it — to understand how the site is used so we can improve it. Choose what you are happy with below. You can change your mind at any time from Manage Cookies in the footer.
A free account takes a minute and lets you:
Citing LIPID MAPS in your publications shows the impact of the resource and helps keep it free for everyone. The citation page lists the papers to cite for each database and tool.